Efficacy and Safety of Cagrilintide and Cagrisema Versus Semaglutide as Anti-Obesity Medications: A Systematic Review, Meta-Analysis and Meta-Regression - PubMed
6 hours ago
- #GLP-1
- #Obesity
- #Weight Management
- Cagrisema showed significantly greater weight loss (percentage and absolute) compared to semaglutide in individuals with obesity.
- Cagrilintide monotherapy's weight loss was comparable to semaglutide, but it had a higher risk of serious adverse events.
- Lipid parameters were mostly similar between groups, with a modest increase in LDL-C for combination therapy vs. semaglutide.
- Cagrisema increased administration-site conditions and nausea compared to semaglutide but had a comparable overall safety profile.
- The study concludes that Cagrisema is more effective than semaglutide for weight loss and glycemic control, with potential in dual-agonist therapy for obesity.